hyperkalemia

Toxicity knocks Ardelyx's hyperkalemia hopes back to preclinic

Unexpected side effects have spelled the end for Ardelyx’s drug candidate to treat elevated potassium levels in the blood, which was in phase 3 testing.

Phil Taylor Nov 21, 2017 9:15am

Struggling Ardelyx cuts staff, places bets on its late-stage pipeline

Aug 9, 2017 9:26am

EuroBiotech Report: AstraZeneca, Novartis, $30M round and more

Mar 23, 2017 9:49am

AstraZeneca’s $2.7B ZS-9 rejected again by FDA

Mar 17, 2017 7:06am

AstraZeneca’s FDA delayed ZS-9 gains European thumbs-up

Feb 24, 2017 7:31am

Relypsa finally finds a buyer as Galenica coughs up $1.5B

Jul 21, 2016 7:51am